๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
DrugsAmrubicin·Lurbinectedin·Ifinatamab Deruxtecan·Topotecan
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
By invitation
A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus
NCT06925334Type 2 Diabetic Patients
DrugDegludec insulin
Beijing Tsinghua Chang Gung Hospital
Phase 4
170
Beijing
2024-05-20
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Recruiting
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
NCT06824883Extranodal NK/T-cell Lymphoma
Peking Union Medical College Hospital
Phase 2
49
Beijing
2024-05-20
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Active, closed
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
NCT06382129Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
698
Beijing
2024-05-17
By invitation
Protocol for Evaluating Physiological and Psychological Adaptation Mechanisms in Tibetan Plateau Environments
NCT06557928High Altitude
Peking Union Medical College Hospital
Observational
17
Beijing
2024-05-17
Active, closed
The Treatment of PD-1 Antibody Combined With Peg-IFNฮฑ in NAs-suppressed CHB Patients
NCT06357806Chronic Hepatitis B
DrugsPeg-IFNฮฑ-2b·Sintilimab
Beijing 302 Hospital
Not applicable
45
Beijing
2024-05-17
Recruiting
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
NCT06421298Lung Cancer
DrugsTafolecimab·Sintilimab·Nab-paclitaxel·Docetaxel
Jinghui Wang
Phase 2
30
Beijing
2024-05-17
Recruiting
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
NCT06420973Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
54
Beijing
2024-05-16
Recruiting
GDFT on the Postoperative Outcome in Head and Neck Cancer Surgery
NCT06468852Postoperative Complications
Beijing Tongren Hospital
Not applicable
340
Beijing
2024-05-16
Recruiting
A Study of MT027 in Patients with Pleural Malignant Tumors
NCT06726564Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1
18
Beijing
2024-05-15
Active, closed
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
NCT06396039Relapsing Multiple Sclerosis
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Active, closed
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
NCT06429904Locally Advanced Pancreatic Cancer
DrugsNalirifox·Nimotuzumab
Peking Union Medical College Hospital
Phase 2
31
Beijing
2024-05-15
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naรฏve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138Hematologic Malignancies
DrugsICP-248·Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
Clinical Outcome in Patients With INPH
NCT06428734Hydrocephalus, Idiopathic Normal Pressure Hydrocephalus, CSF, Glympathic System
Xuanwu Hospital, Beijing
Observational
200
Beijing
2024-05-15
Not yet open
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
NCT06340490Systemic Lupus Erythematosus
Guangdong Ruishun Biotech Co., Ltd
Phase 1
24
Beijing, Nanjing, Shanghai
2024-05-15
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naรฏve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
30
Beijing, Guangzhou, Shanghai, Shenzhen
2024-05-14
Recruiting
Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules
NCT07773064Coronary Artery Disease
Beijing Hospital
Observational
3,000
Beijing
2024-05-14
Recruiting
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
NCT06202625Thrombocytopenia, Stem Cell Transplant Complications
Peking University People's Hospital
Phase 2/3
142
Beijing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-05-13
Recruiting
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
NCT07234162Peripheral T-cell Lymphoma
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Recruiting
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
NCT06421831Spinal Muscular Atrophy Type 3
GeneCradle Inc
Phase 1/2
21
Beijing
2024-05-10
Recruiting
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
NCT06413992Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
DrugsFluzoparib·Camrelizumab·Paclitaxel·Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
117
Beijing
2024-05-10
Recruiting
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
NCT06394492Ovarian Cancer
DrugsSHR-A1921·Topotecan·Doxorubicin·Paclitaxel
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
440
Beijing, Hangzhou
2024-05-10
Recruiting
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
NCT06436677Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma
Peking University First Hospital
Observational
100
Beijing
2024-05-09
Active, closed
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
NCT05795140Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals
Phase 3
65
Beijing
2024-05-08
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888Metastatic Pancreatic Cancer
DrugsSurufatinib·Nab-paclitaxel·Gemcitabine
Hutchmed
Phase 2/3
502
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong
2024-05-08
Recruiting
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Recruiting
A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE
NCT06380309Advanced Malignant Solid Tumor of Digestive System
Peking University
Phase EARLY_PHASE1
89
Beijing
2024-05-06
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,700
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-05-06
Active, closed
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
NCT06391710Heart Failure With Preserved Ejection Fraction
DrugHRS9531
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
203
Beijing
2024-05-06
By invitation
Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
NCT06405295Breast Carcinoma, BRCA Mutation, Adjuvant Drug Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2024-05-06
By invitation
Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients
NCT06405269Breast Neoplasms, Lipid Profile
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2024-05-06
Recruiting
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
NCT06342466Systemic Amyloidosis
DrugsBortezomib·Pomalidomide·Dexamethasone
Jin Lu, MD
Phase 2
40
Beijing
2024-05-06
Recruiting
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
NCT06377735Squamous Cell Carcinoma
Sun Yat-sen University
Not applicable
85
Beijing
2024-05-01
By invitation
Personalized Brain Stimulation for Cognitive Impairment in Older Adults
NCT07208734Alzheimer s Disease
Xuanwu Hospital, Beijing
Not applicable
460
Beijing
2024-05-01
Recruiting
Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency
NCT06655389Sepsis Cardiac Insufficiency
Dongzhimen Hospital, Beijing
Observational
30
Beijing
2024-05-01
Recruiting
Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis
NCT06392737Prostate Cancer
Peking University First Hospital
Not applicable
360
Beijing
2024-05-01
Recruiting
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
NCT07282262Biliary Tract Cancer
DrugsIvosidenib·Lenvatinib
Peking Union Medical College Hospital
Phase 2
300
Beijing
2024-05-01
Active, closed
Hemodialysis-Induced Renal Perfusion Decline: Unraveling the Pathophysiological Mechanisms Linking Intradialytic Circulatory Stress to Residual Renal Function Loss
NCT07003828End-Stage Renal Disease Requiring Haemodialysis
Yuanjun Yang
Observational
30
Beijing
2024-05-01
Active, closed
Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome
NCT06464653Lennox Gastaut Syndrome
Liankun_Ren
Not applicable
5
Beijing
2024-05-01
Active, closed
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer
NCT06419673Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
240
Beijing
2024-05-01
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
DrugCardonilizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Not yet open
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT06254599Non-small Cell Lung Cancer
DrugCrizotinib
Shouyao Holdings (Beijing) Co. LTD
Phase 3
255
Beijing
2024-05-01
Recruiting
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
NCT06638034FAP- Expressing Positive Tumors, RGD- Expressing Positive Tumors
Peking Union Medical College Hospital
Phase EARLY_PHASE1
15
Beijing
2024-05-01
Not yet open
A Study on Factors of Biochemical Response in Autoimmune Hepatitis
NCT06356506Autoimmune Hepatitis
Beijing Friendship Hospital
Observational
630
Beijing
2024-05-01
Recruiting
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
NCT06389422Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis
DrugPembrolizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-05-01
Recruiting
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352Advanced Solid Tumors
DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Beijing, Hangzhou, Wenzhou, Chengdu, Guangzhou
2024-05-01
Recruiting
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
NCT06405139Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
36
Beijing
2024-05-01
Recruiting
Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells
NCT06302465Malignant Bone Tumor
Peking University People's Hospital
Not applicable
60
Beijing
2024-05-01
Not yet open
Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke
NCT06374823Critical Care, Hyperchloremia, Hemorrhagic Stroke
Capital Medical University
Phase 4
342
Beijing
2024-05
Not yet open
Clinical Study of Allogeneic Vฮณ9Vฮด2 T Cells in the Treatment of Brain Malignant Glioma
NCT06396481GBM, DIPG Brain Tumor, Medulloblastoma
Beijing Tiantan Hospital
Phase EARLY_PHASE1
25
Beijing
2024-04-30
Recruiting
The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
NCT06958627HER2 Positive Breast Cancer, Pyrotinib Treatment
DrugPyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
964
Beijing
2024-04-30
Recruiting
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT06385925Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLY3650150
Eli Lilly and Company
Phase 3
510
Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou
2024-04-29
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugBirelentinib
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDato-DXd·Osimertinib
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
NCT05485961End Stage Kidney Disease
DrugCSL300
CSL Behring
Phase 2/3
3,110
Baotou Shi, Beijeing, Beijing, Chengdu, Dalian, Deyang Shi, Dongguan, Foshan Shi
2024-04-27
Recruiting
3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities
NCT06306326Adipocytes, Autografts, Imaging, Three-Dimensional / Methods
Peking University
Not applicable
100
Beijing
2024-04-27
Recruiting
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
NCT07437404Haemophilia A
Sinocelltech Ltd.
Phase 3
36
Beijing
2024-04-26
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069Acute Myeloid Leukemia
DrugHMPL-306
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLY3650150
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Recruiting
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
NCT06685978Hyperplasia of Mammary Glands
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
NCT07187882Vitiligo
Peking University People's Hospital
Not applicable
30
Beijing
2024-04-25
Active, closed
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
NCT06280716Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 3
301
Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Haikou, Shijiazhuang
2024-04-24
Active, closed
Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis
NCT06365697Carotid Artery Stenosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Active, closed
Evolve China PMCF Study
NCT06368622Intracranial Aneurysm
Stryker Neurovascular
Observational
500
Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao
2024-04-24
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
NCT06343948HR+HER2- Breast Cancer
DrugsVinorelbine·Eribulin·Iza-bren·Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
383
Beijing
2024-04-24
Recruiting
An ISO Principle-Based Music Intervention for Reducing Stress, Anxiety, and Depression
NCT07055061Stress, Anxiety, Depression in Adults
Shanghai Mental Health Center
Not applicable
2,000
Beijing
2024-04-23
Recruiting
Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension
NCT06429579Pulmonary Artery Hypertension
China National Center for Cardiovascular Diseases
Not applicable
120
Beijing
2024-04-23
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugRomosozumab
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Active, closed
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients
NCT06322628Nash
Visirna Therapeutics HK Limited
Phase 2
48
Beijing
2024-04-22
Recruiting
Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria
NCT06819774Acute Urticaria
Shandong New Time Pharmaceutical Co., LTD
Phase 3
284
Beijing
2024-04-22
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Recruiting
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction
NCT06374667Stroke, Acute Ischemic, Blood-Brain Barrier
yilong Wang
Not applicable
134
Wuhu, Beijing, Tangshan, Xi'an, Tianjin
2024-04-22
Active, closed
Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
NCT06603142Primary Gout, Hyperuricemia
Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd
Phase 2/3
636
Beijing
2024-04-22
Recruiting
Mobile Internet-based Remote Home Rehabilitation Improves Prognostic Function and Life Quality in Pulmonary Hypertension
NCT06362382Pulmonary Hypertension
China-Japan Friendship Hospital
Not applicable
80
Beijing
2024-04-22
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Paclitaxel·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 1/2
287
Beijing, Cheng Du Shi, Linyi, Shanghai, Wuhan
2024-04-22
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
DrugsOsimertinib·Pemetrexed·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Not yet open
DBS for Treatment-resistant Obsessive-compulsive Disorder
NCT06360991Obsessive-Compulsive Disorder (OCD)
Xuanwu Hospital, Beijing
Not applicable
60
Beijing
2024-04-20
Not yet open
Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome
NCT06361004Tourette's Syndrome
Xuanwu Hospital, Beijing
Not applicable
60
Beijing
2024-04-20
Recruiting
99mTc-CNDG SPECT/CT in Brain Tumors
NCT06362304Intracranial Tumor
Peking Union Medical College Hospital
Not applicable
30
Beijing
2024-04-20
Recruiting
Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
NCT06391736Pompe Disease (Late-onset)
GeneCradle Inc
Phase 1/2
33
Beijing
2024-04-19
Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
NCT06375473Pancreatic Cancer
DrugIrinotecan liposome II combination therapy
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06349811Locally Advanced or Metastatic Solid Tumors
DrugBL-M05D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
30
Beijing
2024-04-19
Recruiting
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
NCT06928376Acute Myeloid Leukemia, First Line Therapy
DrugsAclacinomycin·Azacytidine·Granulocyte Colony-Stimulating Factor·Chidamide
Chinese PLA General Hospital
Phase 2
160
Beijing
2024-04-18
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Cheng Du Shi, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Recruiting
Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours
NCT06397963Solid Tumor, Adult
DrugGT307
Grit Biotechnology
Not applicable
18
Beijing, Xuzhou
2024-04-18
Active, closed
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
NCT06394414Advanced Solid Tumors
DrugSerplulimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
Recruiting
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
NCT06323525Non-hodgkin Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2024-04-17
Recruiting
Changes in Intravenous Anesthetic Drug Dosage in Insomnia Patients Undergoing Digestive Endoscopy
NCT06376760Insomnia, Digestive Endoscopy
Beijing Tiantan Hospital
Observational
3,360
Beijing
2024-04-17
Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
NCT07011186Myeloid Malignancy
DrugsTQB3909·Azacitidine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
NCT06405490Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine
DrugsNanoliposomal Irinotecan·Cadonilimab·Oxaliplatin·Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-04-17
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Recruiting
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
NCT06417892Gastric Cancer
DrugsPD-1inhibitor·Albumin paclitaxel·Fruquintinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60
Beijing
2024-04-15
By invitation
Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis
NCT06452173Carotid Stenosis
Beijing Tiantan Hospital
Observational
300
Beijing
2024-04-15
Recruiting
The Application of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU
NCT06341062Intensive Care Unit, Acute Kidney Injury, Ultrasound
Peking University Third Hospital
Observational
44
Beijing
2024-04-15
Rows per page Showing 3501–3600 of 5484
Previous 34 35 36 37 38 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=36

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.